Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Transcription elongation factor A protein 3 (TCEA3) is a member of the TFIIS family, necessary for efficient elongation of transcription by RNA polymerase II, particularly beyond template-encoded arrest sites that stall polymerase progression. TCEA3 is highly involved in muscle biology, as its expression increases during myoblast differentiation and it enhances the transcriptional activity of myogenic regulatory factors such as MyoD and Myogenin. Its mechanism ensures the release of stalled polymerase complexes, thereby accelerating the expression of genes critical for muscle development, maturation, regeneration, and repair. Evidence also links TCEA3 to the pathogenesis of rhabdomyosarcoma and suggests it may be a future target in muscle-related diseases and regenerative therapies[1][3][4][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Transcription elongation factor A protein 3 (TCEA3).